Program
datopotamab deruxtecan
Also written as “Dato-DXd”, “Datopotamab deruxtecan” and “Datopotamab Deruxtecan”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Triple Negative Breast Neoplasms · Endometrial Neoplasms · Urinary Bladder Neoplasms, led by 2 companies.
Drug pageDatopotamab deruxtecan: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 2121 open or running | phase 3since Oct 4, 2021 | Oct 25, 2018 | Jan 11, 2027phase 3 · NCT06417814 |
| Daiichi Sankyo | 87 open or running | phase 3since Nov 19, 2020 | Jan 9, 2018 | Jan 1, 2028phase 1 · NCT03401385 |
Also a collaborator on its studies: Merck and Parexel.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentAstraZeneca develops it with Daiichi Sankyo, worldwide except Japan, where Daiichi Sankyo keeps the rights.Announced Jul 27, 2020 · Source: Daiichi Sankyo and AstraZeneca (release), Jul 27, 2020
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 9, 2018First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT03401385 · 890 enrolled · United States, Japan
- Dec 9, 2019Named datopotamab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 122
- Jul 20, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04484142 · 137 enrolled · United States, France, Germany and more
- Jul 27, 2020AstraZeneca develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Daiichi Sankyo and AstraZeneca (release)
- Aug 21, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04526691 · 145 enrolled · United States, Italy, Japan and more
- Nov 19, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04656652 · 605 enrolled · United States, Argentina, Australia and more
- Jan 18, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05215340 · 740 enrolled · United States, Argentina, Australia and more
- Sep 22, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05555732 · 1,233 enrolled · United States, Argentina, Australia and more
- Aug 12, 2025Phase 3 study in Urinary Bladder NeoplasmsNCT07129993 · 630 planned · United States, Austria, China and more
- Oct 16, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07890714 · 268 planned · Taiwan
Ahead
- Jan 1, 2028Primary completion: phase 1 study in Triple Negative Breast NeoplasmsNCT03401385
- May 11, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05555732
- Jun 1, 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT07129993
- Sep 30, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07890714
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) ”NCIt, by rule
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 8 Daiichi Sankyo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07890714Carcinoma, Non-Small-Cell Lung · Taiwan | 2 | Recruiting | Sep 30, 2029 | 268 |
| NCT07129993Urinary Bladder Neoplasms · United States, Austria, China and more | 3 | Recruiting | Jun 1, 2029 | 630 |
| NCT05555732Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 11, 2029 | 1,233 |
| NCT05215340Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 4, 2030 | 740 |
| NCT04656652Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 10, 2024 | 605 |
| NCT04526691Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more | 1 | Active, not recruiting | Apr 14, 2024 | 145 |
| NCT04484142Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Completed | Mar 10, 2023 | 137 |
| NCT03401385Triple Negative Breast Neoplasms · United States, Japan | 1 | Active, not recruiting | Jan 1, 2028 | 890 |
How it is read
Names in the registry
- “Dato-DXd”, 13 entries
- “Datopotamab deruxtecan”, 5 entries
- “Datopotamab Deruxtecan”, 5 entries
- “Datopotamab deruxtecan (Dato-DXd)”, 2 entries
- “Datopotamab Deruxtecan (Dato-DXd)”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 18 studies
- Breast Neoplasms, 6 studies
- Triple Negative Breast Neoplasms, 2 studies
- Endometrial Neoplasms, 1 study
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.